ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2025
Impact of pneumococcal urinary antigen testing on clinical outcomes in patients hospitalized with community-acquired pneumonia.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Evolving Approaches to Bacterial Identification: A Review of Classical and Modern Techniques.International journal of molecular sciences · 2026Review
- Rethinking Pneumococcal Urinary Antigen Testing in the Emergency Department: From Reflex Testing to Reasoned Use.Cureus · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To establish a microbiological etiology in severe community-acquired pneumonia (CAP), most guidelines recommend adding urinary antigen tests (UAT) to respiratory sampling. However, their usage and impact remain unclear. We examined the clinical impact of UAT in hospitalized CAP patients. This multicenter cohort study included patients admitted with CAP at three hospitals in Denmark from 2017 to 2020. Logistic regression and propensity-score matching were applied to assess the effect of UAT on 30-day mortality, targeted antibiotic treatment and atypical antibiotic coverage. Propensity-score matching was applied to adjust for confounding. Of 2,449 patients included, 654 (27%) had UAT performed within 48 hours of admission. Streptococcus pneumoniae was detected in 8.0% (52/654). 30-day mortality was 11.8% in the tested group and 10.2% in the untested group (adjusted odds ratio [aOR] 1.17, 95% CI 0.83-1.65). Broad-spectrum antibiotics were administered to 47.9% of tested and 42.4% of untested patients (aOR 1.25, 95% CI 1.00-1.55) at discharge. Overall, there were 212 pneumococcal cases, with 30/212 (14%) solely detected by UAT. Of patients with positive pneumococcal UAT, 26% received broad-spectrum antibiotics at discharge, compared with 46% of UAT-negative patients (aOR 0.41, 95% CI 0.18-0.96). Mortality was similar in tested and untested patients. Tested patients received more broad-spectrum antibiotic treatment than untested patients, while patients with positive pneumococcal UAT received more narrow-spectrum antibiotics. Of all pneumococcal cases, 14% were diagnosed exclusively by UAT, suggesting usefulness in antimicrobial stewardship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.